BusinessCombination Immunotherapy of Pembrolizumab with the Galectin-3 Inhibitor GR-MD-02 Shows Promising Early Results in Treatment of Advanced Melanoma from a Phase 1b Clinical TrialBy Nasdaq OMXNov 13, 2017, 1:31 PM UTC
BusinessPROVECTUS ANNOUNCES PRELIMINARY RESULTS FROM PHASE 1B TRIAL OF INTRALESIONAL PV-10 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) FOR THE TREATMENT OF STAGE IV MELANOMABy Nasdaq OMXOct 18, 2017, 1:38 PM UTC
BusinessBiothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)By Nasdaq OMXFeb 23, 2017, 2:01 PM UTC
BusinessBiothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)By Nasdaq OMXFeb 23, 2017, 2:01 PM UTC
